- Akkermansia muciniphila is a gut bacterium that lives in the mucus layer of the intestine.
- Its secreted protein P9 was shown to trigger GLP-1 release from gut cells (Yoon et al., Nature Microbiology, 2021). That study did not measure GLP-2.
- The often-cited GLP-2 experiment (Cani et al., Gut, 2009) tested a prebiotic fibre in preclinical models, not Akkermansia. No study has tested whether Akkermansia acts through GLP-2.
- Pasteurised Akkermansia was authorised as a novel food in the EU in 2021. It is a food ingredient, not a medicine.
- FUT2 non-secretor status, common in people of Northern European descent, changes the sugars on gut mucus. No study has tested whether it changes response to an Akkermansia product.
Akkermansia muciniphila is a bacterium that lives in the mucus coating the gut wall. It is sold as a supplement, often with claims that it raises GLP-2 and repairs the gut lining. Some of that rests on measured results and some on inference. Here is which is which.
This page is education about published research. It does not recommend any supplement, product or food plan, and it is not medical advice.
What has the P9 protein been shown to do?
The one Akkermansia molecule that has been isolated and tested on its own was described by Yoon and colleagues in Nature Microbiology in 2021. The bacterium secretes a protein they named P9. Purified P9 bound a surface protein called ICAM-2 on L-cells, the hormone-releasing cells of the gut lining, and stimulated GLP-1 release, with no live bacteria present. The study followed glucose handling; it did not measure GLP-2.
A 2025 laboratory study in Nutrients also reported increased GLP-1 secretion from human L-cells exposed to Akkermansia extract in a dish.
Because L-cells make GLP-1 and GLP-2 from the same parent protein, claims about GLP-2 are often attached to these results. That is an inference. Neither study measured GLP-2.
What about the GLP-2 experiment people cite?
The study usually cited for the GLP-2 step is Cani et al., Gut, 2009. In preclinical models of obesity, a prebiotic fibre (oligofructose) changed the gut bacteria and improved gut barrier measures, and blocking the GLP-2 receptor removed that improvement.
That experiment tested a fibre, not Akkermansia. No published study has blocked the GLP-2 receptor and then tested Akkermansia directly. The GLP-2 route is plausible and untested.
A separate route has been described: Chelakkot and colleagues (Experimental and Molecular Medicine, 2018) reported that membrane vesicles shed by Akkermansia increased the proteins that form the seals between gut lining cells in laboratory and preclinical work. That route does not depend on GLP-2.
Why pasteurised products exist
P9 is heat-stable, which is part of the reason pasteurised Akkermansia is studied at all. The European Food Safety Authority assessed pasteurised Akkermansia and it was authorised as a novel food in the EU in 2021. That is a food safety authorisation, not evidence that it treats any condition.
What does genetics research say about gut mucus?
Akkermansia feeds on the sugar chains attached to gut mucus, and which sugars are present is partly inherited.
FUT2 encodes an enzyme that attaches fucose to mucus proteins. People with a working copy are called secretors; non-secretors carry an inactive copy. Roughly one in five people of Northern European descent are non-secretors. Non-secretor status is also known for conferring resistance to some norovirus strains, which use the same sugar structures. Some microbiome studies have reported differences in gut bacteria, including bifidobacteria, by secretor status; findings for Akkermansia are not consistent.
MUC2 encodes the main protein of the mucus layer. Variants have been studied in inflammatory bowel conditions.
No study has tested whether FUT2 or MUC2 genotype changes response to an Akkermansia product. A DNA report can show your secretor status and what the microbiome research found; it cannot predict how any supplement would affect you.
Is there a GLP-2 drug?
Yes. Teduglutide (Gattex) is an FDA-approved GLP-2 analog for short bowel syndrome in people who depend on intravenous nutrition. It is a prescription drug with specialist oversight. Glepaglutide, another analog, received an FDA Complete Response Letter in December 2024. The GLP-2 research summary covers those trials.
Verdict: Akkermansia's P9 protein has been shown to trigger GLP-1 release from gut cells. The step to GLP-2 and gut repair has not been tested directly, and the experiment usually cited for it used a fibre, not the bacterium. FUT2 secretor status shapes gut mucus, but no study has tested whether it changes response to an Akkermansia product.
Watch
What clinicians and researchers say about GLP-2
Frequently asked questions
What does Akkermansia muciniphila do?
Akkermansia lives in the mucus layer of the gut. Its secreted protein P9 has been shown to trigger GLP-1 release from L-cells in the gut lining (Yoon et al., Nature Microbiology, 2021). Vesicles it sheds have been linked to increased gut barrier proteins in laboratory work. Claims that it raises GLP-2 or repairs the gut have not been tested directly.
Has anyone shown Akkermansia works through GLP-2?
No. The study usually cited, Cani et al. in Gut (2009), tested a prebiotic fibre in preclinical models and found that blocking the GLP-2 receptor removed its barrier benefit. No published study has tested Akkermansia itself with GLP-2 blocked.
Why is pasteurised Akkermansia sold?
The active protein identified so far, P9, is heat-stable. Pasteurised Akkermansia was authorised as a novel food in the EU in 2021. That is a food safety authorisation, not evidence that it treats any condition.
What is FUT2 secretor status?
FUT2 encodes an enzyme that adds fucose to gut mucus. Non-secretors, roughly one in five people of Northern European descent, carry an inactive copy. Some microbiome studies report differences in gut bacteria by secretor status, but no study has tested whether it changes response to an Akkermansia product.
Is there an approved GLP-2 drug?
Yes. Teduglutide (Gattex) is FDA-approved for short bowel syndrome in people who depend on intravenous nutrition. It is a prescription drug used under specialist care.
This article is for informational and educational purposes only. It reports what published research found; it is not medical advice, it does not diagnose, treat, cure or prevent any disease, and nothing in it is a dose or a recommendation to use any compound. Talk to a licensed clinician about any medical decision.